Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children (for specialized target groups only)

Source: Bayer Company News - Category: Pharmaceuticals Source Type: news